Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Craig Saran

Pain Medicine Glendale, AZ Doctor of Osteopathy

NPI 1508125709 CMS profile 1391530

7200 W Bell Rd Ste F101, Glendale, AZ 85308

Open in the dashboard

General payments

$13,814

271 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Craig Saran of Glendale, AZ is reported in the CMS Open Payments database as having received $13,814 across 271 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,341 60
2024 General $3,837 61
2023 General $1,072 25
2022 General $614 17
2021 General $1,214 34
2020 General $849 26
2019 General $2,887 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Craig Saran
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Craig Saran were reported at $3,341. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Craig Saran Pain Medicine median Middle half National median
2019 $2,887 $498 $126–$1,682 $163
2020 $849 $284 $80–$910 $114
2021 $1,214 $399 $112–$1,219 $132
2022 $614 $455 $137–$1,484 $149
2023 $1,072 $484 $128–$1,495 $160
2024 $3,837 $498 $131–$1,540 $164
2025 $3,341 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $4,945 58 payments
  2. Vertiflex, Inc. $2,048 19 payments
  3. BIOTRONIK NRO, Inc. $1,695 45 payments
  4. Nalu Medical, Inc. $1,413 44 payments
  5. Medtronic USA, Inc. $996 31 payments
  6. Medtronic, Inc. $406 7 payments
  7. Vertos Medical, Inc. $306 8 payments
  8. NuVasive, Inc. $304 3 payments
  9. Nevro Corp. $290 6 payments
  10. Stryker Corporation $248 4 payments
  11. Other $1,164 46 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,728 256 payments
  2. Travel and Lodging $2,964 12 payments
  3. Consulting Fee $1,110 2 payments
  4. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. Superion ISS $2,048 19 payments
  2. Nalu Neurostimulation System $1,413 44 payments
  3. Intracept $1,160 5 payments
  4. INTELLIS $966 29 payments
  5. Prospera Not Applicable $869 17 payments
  6. Prospera Not Applicable $707 24 payments
  7. NA $555 1 payment
  8. Click $432 4 payments
  9. Avista MRI $336 3 payments
  10. INTELLIS ADAPTIVESTIM $313 4 payments
  11. Other $3,568 99 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

2,252

Median for Pain Management: 951

Drug cost

$74,727

Median for Pain Management: $26,034

Branded share of claims

31.3%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine Generic 61 $12,717
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 325 $9,345
Xtampza Er Oxycodone Myristate Brand 15 $8,395
Oxycodone Hcl Generic 487 $7,735
Oxycontin Oxycodone Hcl Brand 12 $6,003
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 210 $4,973
Pregabalin Generic 98 $3,995
Morphine Sulfate Er Morphine Sulfate Brand 120 $3,331
Gabapentin Generic 159 $3,118
Fentanyl Generic 27 $2,382

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$571,946

Of which drugs: $1,846

Medicare patients

568

Average age 73

Services billed

7,896

349 women, 219 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 34%
Diabetes 33%
Ischemic heart disease 33%
Chronic kidney disease 30%
COPD 23%
Osteoporosis 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 48 242 $175
Injection, ketorolac tromethamine, per 15 mg J1885 Office 18 56 $28

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

271 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record